Cantargia: Fast Track in IL1-RAP High Patients
11 juni, 10:07
11 juni, 10:07
The fast-track designation from the FDA in metastatic pancreatic cancer confirms Cantargia's strategy of developing nadunolimab in patients high IL1RAP expression levels. Redeye provides a brief comment.
11 juni, 10:07
The fast-track designation from the FDA in metastatic pancreatic cancer confirms Cantargia's strategy of developing nadunolimab in patients high IL1RAP expression levels. Redeye provides a brief comment.
Veckans analyser
Fortnox-budet
Veckans analyser
Fortnox-budet
1 DAG %
Senast
Creades
13 juni, 18:51
Creades och Bure gör stor halvledarinvestering
OMX Stockholm 30
1 DAG %
Senast
2 459,61